168 related articles for article (PubMed ID: 35213032)
1. Preclinical Evaluation of the Renal Toxicity of Oligonucleotide Therapeutics in Mice.
Echevarría L; Goyenvalle A
Methods Mol Biol; 2022; 2434():371-384. PubMed ID: 35213032
[TBL] [Abstract][Full Text] [Related]
2. Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides.
Goyenvalle A; Jimenez-Mallebrera C; van Roon W; Sewing S; Krieg AM; Arechavala-Gomeza V; Andersson P
Nucleic Acid Ther; 2023 Jan; 33(1):1-16. PubMed ID: 36579950
[TBL] [Abstract][Full Text] [Related]
3. Urinary Kidney Biomarker Panel Detects Preclinical Antisense Oligonucleotide-Induced Tubular Toxicity.
Sandelius Å; Basak J; Hölttä M; Sultana S; Hyberg G; Wilson A; Andersson P; Söderberg M
Toxicol Pathol; 2020 Dec; 48(8):981-993. PubMed ID: 33084520
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxic antisense oligonucleotide SPC5001 induces kidney injury biomarkers in a proximal tubule-on-a-chip.
Nieskens TTG; Magnusson O; Andersson P; Söderberg M; Persson M; Sjögren AK
Arch Toxicol; 2021 Jun; 95(6):2123-2136. PubMed ID: 33961089
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.
Donner AJ; Bell TA; Greenlee S; Graham MJ; Crooke RM
Nucleic Acid Ther; 2018 Oct; 28(5):297-306. PubMed ID: 30133341
[TBL] [Abstract][Full Text] [Related]
6. Intracellular Absolute Quantification of Oligonucleotide Therapeutics by NanoSIMS.
Becquart C; Stulz R; Thomen A; Dost M; Najafinobar N; Dahlén A; Andersson S; Ewing AG; Kurczy ME
Anal Chem; 2022 Jul; 94(29):10549-10556. PubMed ID: 35830231
[TBL] [Abstract][Full Text] [Related]
7. Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Migliorati JM; Liu S; Liu A; Gogate A; Nair S; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
Drug Metab Dispos; 2022 Jun; 50(6):888-897. PubMed ID: 35221287
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Delivery of Ligand-Conjugated Antisense Oligonucleotides (C16-HA-ASO) Targeting Dystrophia Myotonica Protein Kinase Transcripts for the Treatment of Myotonic Dystrophy Type 1.
Ait Benichou S; Jauvin D; De Serres-Bérard T; Bennett F; Rigo F; Gourdon G; Boutjdir M; Chahine M; Puymirat J
Hum Gene Ther; 2022 Aug; 33(15-16):810-820. PubMed ID: 35794764
[TBL] [Abstract][Full Text] [Related]
10. Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Alhamadani F; Zhang K; Parikh R; Wu H; Rasmussen TP; Bahal R; Zhong XB; Manautou JE
Drug Metab Dispos; 2022 Jun; 50(6):879-887. PubMed ID: 35221289
[TBL] [Abstract][Full Text] [Related]
11. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics.
Ramasamy T; Ruttala HB; Munusamy S; Chakraborty N; Kim JO
J Control Release; 2022 Dec; 352():861-878. PubMed ID: 36397636
[TBL] [Abstract][Full Text] [Related]
12. Integrated Assessment of Phase 2 Data on GalNAc
Baker BF; Xia S; Partridge W; Kwoh TJ; Tsimikas S; Bhanot S; Geary RS
Nucleic Acid Ther; 2023 Jan; 33(1):72-80. PubMed ID: 36454263
[TBL] [Abstract][Full Text] [Related]
13. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
15. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs.
Takakusa H; Iwazaki N; Nishikawa M; Yoshida T; Obika S; Inoue T
Nucleic Acid Ther; 2023 Apr; 33(2):83-94. PubMed ID: 36735616
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of [68Ga]Ga-MALAT-1-antisense oligonucleotides for specific PET imaging of MALAT-1 expressing tumours.
Liu ZF; Ye QN; Yang J; Yang M; Pan DH; Dong MJ
Nucl Med Commun; 2021 Jul; 42(7):782-791. PubMed ID: 33625181
[TBL] [Abstract][Full Text] [Related]
17. Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides.
Relizani K; Echevarría L; Zarrouki F; Gastaldi C; Dambrune C; Aupy P; Haeberli A; Komisarski M; Tensorer T; Larcher T; Svinartchouk F; Vaillend C; Garcia L; Goyenvalle A
Nucleic Acids Res; 2022 Jan; 50(1):17-34. PubMed ID: 34893881
[TBL] [Abstract][Full Text] [Related]
18. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs.
Zhang C; Newsome JT; Mewani R; Pei J; Gokhale PC; Kasid UN
Methods Mol Biol; 2009; 480():65-83. PubMed ID: 19085118
[TBL] [Abstract][Full Text] [Related]
19. A fluorescent splice-switching mouse model enables high-throughput, sensitive quantification of antisense oligonucleotide delivery and activity.
Byrnes AE; Roudnicky F; Gogineni A; Soung AL; Xiong M; Hayne M; Heaster-Ford T; Shatz-Binder W; Dominguez SL; Imperio J; Gierke S; Roberts J; Guo J; Ghosh S; Yu C; Roose-Girma M; Elstrott J; Easton A; Hoogenraad CC
Cell Rep Methods; 2024 Jan; 4(1):100673. PubMed ID: 38171361
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Antisense Oligonucleotides Are Coming of Age.
Bennett CF
Annu Rev Med; 2019 Jan; 70():307-321. PubMed ID: 30691367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
